New hemophilia Drug's impact on Kids' joints under investigation
NCT ID NCT07190118
Summary
This study aims to understand how emicizumab, a newer subcutaneous treatment for Hemophilia A, affects the musculoskeletal system in children. Researchers will measure joint health, pain levels, mobility, and quality of life in 20 children under 18 with severe Hemophilia A (factor level ≤1%) who are starting this treatment. The goal is to see if this easier-to-administer treatment leads to better joint protection and daily function compared to traditional therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hasan Kalyoncu University
Gaziantep, Gaziantep, (505) 090-5846, Turkey (Türkiye)
Conditions
Explore the condition pages connected to this study.